Real-World watch: tracking a drug for rare, debilitating fevers
NCT ID NCT06838143
Summary
This study aims to monitor the safety and effectiveness of the drug Ilaris (canakinumab) in real-world clinical settings. It will include children and adults with rare hereditary fever syndromes or a form of juvenile arthritis who are already receiving the drug as part of their standard care. Researchers will collect data over up to four years to see how well the drug controls disease flares and impacts patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.